Astrazeneca PLC (AZN) stock prices updated...
 

Astrazeneca PLC stock price

Astrazeneca PLC latest news:


  • 08/07/2017 12:15:00

    3 High-Yield Stocks for Aggressive Investors

    The high-yield dividend stocks AstraZeneca plc, GameStop, and Las Vegas Sands may be worth checking out right now.

  • 08/01/2017 00:38:12

    AstraZeneca gets breakthrough status for blood cancer drug

    LONDON, Aug 1 (Reuters) - AstraZeneca said on Tuesday that U.S. regulators had awarded its blood cancer drug acalabrutinib "breakthrough" status for the treatment of patients with mantle cell lymphoma, a rare type of blood cancer.

  • 07/31/2017 00:36:15

    AstraZeneca drug gets breakthrough status in early lung cancer

    AstraZeneca(AZN) said on Monday its immunotherapy drug Imfinzi had been granted "breakthrough" designation by U.S. regulators for treating non-metastatic lung cancer, following the success of the so-called Pacific trial.

  • 07/27/2017 15:15:31

    Facebook and Verizon advance while AstraZeneca dives

    Facebook and Verizon Communications trade higher while AstraZeneca and Southwest Airlines drop

  • 07/27/2017 10:43:43

    UPDATE 3-Bristol-Myers shares slump after failed AstraZeneca drug trial

    July 27 (Reuters) - Bristol-Myers Squibb Co shares fell 4 percent on Thursday as investors bet that a failed cancer-drug trial at AstraZeneca Plc would have negative implications for Bristol-Myers' similar immunotherapy treatment regimen.

  • 07/27/2017 01:34:42

    AstraZeneca revenue down as key drugs lose patent protection

    Anglo-Swedish drugmaker AstraZeneca says second-quarter revenue fell amid declining sales of blockbuster drugs Crestor and Seroquel XR, which lost patent protection in the United States last year

  • 07/27/2017 01:28:18

    BRIEF-Astrazeneca says establish strategic oncology collaboration with Merck

    Astrazeneca Plc(AZN): * ASTRAZENECA AND MERCK ESTABLISH STRATEGIC ONCOLOGY COLLABORATION. * Astrazeneca Plc(AZN) - ASTRAZENECA AND MERCK WILL INDEPENDENTLY DEVELOP AND COMMERCIALISE LYNPARZA AND POTENTIAL MEDICINE SELUMETINIB IN COMBINATIONS WITH COMPANIES' RESPECTIVE. * MERCK WILL PAY CO UP TO $8.5 BILLION IN TOTAL CONSIDERATION.

  • 07/27/2017 01:27:20

    AstraZeneca drags down FTSE 100

    The drugmaker is the biggest loser on the index after its share price falls more than 15%.

  • 07/27/2017 00:33:33

    AstraZeneca lung cancer study fails in big setback for company

    AstraZeneca's(AZN) combination of two immunotherapy drugs, durvalumab and tremelimumab, failed to help patients as hoped in a closely watched advanced lung cancer trial, the British company said on Thursday.

  • 07/27/2017 00:33:15

    UPDATE 1-AstraZeneca lung cancer study fails in big setback for company

    LONDON, July 27 (Reuters) - AstraZeneca's combination of two immunotherapy drugs, durvalumab and tremelimumab, failed to help patients as hoped in a closely watched advanced lung cancer trial, the British company said on Thursday.

  • 07/27/2017 00:19:17

    AstraZeneca lung cancer drug combination misses goal in key study

    LONDON, July 27 (Reuters) - AstraZeneca's combination of two immunotherapy drugs, durvalumab and tremelimumab, failed to help patients as hoped in a closely watched advanced lung cancer trial, the British company said on Thursday. (Reporting by Ben Hirschler)

  • 07/14/2017 14:34:56

    AstraZeneca says CEO Pascal Soriot will host earnings call

    Anglo-Swedish pharmaceutical firm AstraZeneca (AZN) said on Friday its chief executive, Pascal Soriot, would host a results call with reporters on July 27, after refusing to comment on speculation this week that he was leaving the firm.

  • 07/14/2017 14:32:21

    UPDATE 2-AstraZeneca says CEO Pascal Soriot will host earnings call

    LONDON, July 14 (Reuters) - Anglo-Swedish pharmaceutical firm AstraZeneca said on Friday its chief executive, Pascal Soriot, would host a results call with reporters on July 27, after refusing to comment on speculation this week that he was leaving the firm.

  • 07/14/2017 13:07:56

    AstraZeneca offers no comment after report saying CEO staying

    LONDON, July 14 (Reuters) - Anglo-Swedish pharmaceutical firm AstraZeneca declined to comment on speculation about the future of its chief executive Pascal Soriot on Friday, after a report quoted Bloomberg news agency saying he would stay in his post.

  • 07/12/2017 13:18:57

    AstraZeneca's CEO Soriot to join Israeli drugs company Teva-report

    Israel-based Teva Pharmaceutical Industries (TEVA) will name AstraZeneca (AZN) chief executive Pascal Soriot as its next CEO, the Calcalist financial news website said on Wednesday. Soriot has met with Teva representatives and expressed his agreement to serve as its next CEO.

  • 06/19/2017 10:26:37

    GSK's new pharma head to join in September after AstraZeneca tussle

    LONDON (Reuters) - GlaxoSmithKline has struck a deal for Luke Miels to start as its new head of pharmaceuticals in September, following a lengthy dispute over his contract with his former employer AstraZeneca.

  • More trends:

    AT&T Inc.T | Atento S.A.ATTO | Atlantic Power CorporationAT | Atlas EnergyATLS | Atlas Resource PartnersARP | Atlas Resource PartnersARP^D | Atlas Resource PartnersARP^E | Atmos Energy CorporationATO | Atwood OceanicsATW | AU Optronics CorpAUO |